NextBio

Help
Description: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Drug Type: Small Molecule; Approved; Investigational
Indication: Investigated for use/treatment in transplant (rejection) and renal cell carcinoma.
View Complete Description



Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving rad001.

View All Author iconAuthors
  • Heidi A Lane
  • Terence O'Reilly
  • George Thomas
  • Jerome Tamburini
  • Hector M Garcia-Garcia
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Dana-Farber Cancer Institute
  • M.D. Anderson Cancer Center
  • Novartis Pharmaceuticals
  • Emory University
  • University of California, San Francisco
View All Affiliations icon Organizations
  • Novartis Institutes for BioMedical Research
  • Memorial Sloan-Kettering Cancer Center
  • Dana-Farber Cancer Institute
  • University of Texas M.D. Anderson Cancer Center
  • Friedrich Miescher Institute for Biomedical Research

Clinical Trials | 170 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “rad001”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “rad001”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio